
A rise in the use of attention deficit and hyperactivity disorder drugs has helped push Shire’s turnover past $4 billion …
The European Medicines Agency has approved a second manufacturing facility in the USA for Shire’s Fabry disease treatment Replagal. Shire’s …
UK drugmaker Shire has completed construction of a new manufacturing facility for its orphan disease drugs Replagal and Vpriv, and …

